Bain Capital Life Sciences Raises Fourth Fund

Bain Capital Life Sciences Raises $1.3 Billion for Fourth Fund

Bain Capital Life Sciences, a leading global healthcare investment firm, today announced the final closing of its fourth fund, Bain Capital Life Sciences IV, L.P. ("Fund IV"). Fund IV was significantly oversubscribed, surpassing its initial target and closing at its hard cap of $1.3 billion.

Fund IV will continue Bain Capital Life Sciences' strategy of investing in innovative and transformative healthcare companies across the globe. The firm has a long and successful track record of investing in healthcare, having invested over $5 billion in the sector since its inception in 2005.

Fund IV is led by a team of experienced healthcare investors with deep operating and investing expertise. The team has a proven track record of identifying and investing in promising healthcare companies, helping them to achieve significant growth and value creation.

Fund IV will focus on investing in companies across all stages of development, from early-stage to late-stage growth companies. The firm will continue to invest in a broad range of healthcare subsectors, including biotechnology, medical devices, and healthcare services.

Bain Capital Life Sciences has a global presence, with offices in Boston, New York, London, and Dublin. The firm's global reach allows it to identify and invest in the most promising healthcare companies around the world.

Fund IV has already made a number of investments, including:

• Avalo Therapeutics, a clinical-stage biopharmaceutical company developing novel treatments for cancer
• Bellus Health, a clinical-stage biopharmaceutical company developing novel treatments for chronic cough and other respiratory diseases
• Ribon Therapeutics, a clinical-stage biopharmaceutical company developing novel treatments for cancer

Bain Capital Life Sciences is a leading global healthcare investment firm with a deep understanding of the healthcare industry. The firm's experienced investment team and global presence allow it to identify and invest in the most promising healthcare companies around the world.

Conclusion

Bain Capital Life Sciences' fourth fund is a testament to the firm's strong track record and commitment to investing in the healthcare sector. The fund will provide Bain Capital Life Sciences with the resources to continue to invest in innovative and transformative healthcare companies that have the potential to improve the lives of patients around the world.